Targeted delivery of liposomal chemoimmunotherapy for cancer treatment
Chemoimmunotherapy that utilizes the immunomodulatory effect of chemotherapeutics has shown great promise for treating poorly immunogenic solid tumors. However, there remains a significant room for improving the synergy between chemotherapy and immunotherapy, including the efficient, concurrent deli...
Main Authors: | Yusheng Liu, Joonsu Han, Yang Bo, Rimsha Bhatta, Hua Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1010021/full |
Similar Items
-
Primary adipocytes as targetable drug depot to prevent post-surgical cancer recurrence
by: Yang Bo, et al.
Published: (2024-04-01) -
In Situ Dendritic Cell Recruitment and T Cell Activation for Cancer Immunotherapy
by: Joonsu Han, et al.
Published: (2022-08-01) -
Differential Labeling of Glycoproteins with Alkynyl Fucose Analogs
by: Chenyu Ma, et al.
Published: (2020-08-01) -
Liposomal Delivery of MIW815 (ADU-S100) for Potentiated STING Activation
by: Nan Ji, et al.
Published: (2023-02-01) -
Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy
by: Tianqi Wang, et al.
Published: (2021-04-01)